Drug screening in urine
Material: | 10 ml urine |
Methods: |
Ligandenassays → Enzym-Multiplied-Immunoassay (EMIT) Flüssigkeitschromatographie-Massenspektrometrie (LC-MS/MS) → LC-Tandem-Massenspektrometrie Ligandenassays → Cloned Enzyme Donor Immunoassay (CEDI) | Reference range | See findings report |
Indication | Suspicion of drug abuse, intoxication, abstinence checks |
Please note | Simple drug screening (abbreviation: DRU1): Test for cannabinoids, cocaine, benzoylecgonine, amphetamines, methamphetamines, MDA, MDMA, opiates, methadone or EDDP by immunoassay.
Standard drug screening (abbreviation DRU2): Test for cannabinoids, cocaine, benzoylecgonine, amphetamines, methamphetamines, MDA, MDMA, opiates, methadone or EDDP by immunoassay as well as test for opiates, benzodiazepines via LC-MS/MS. When this test series is requested, we use a chromatographic method (LC-MS/MS) in addition to the immunological tests, especially for the differentiation of opiates (Morphine, 6-monoacetylmorphin, codeine, dihydrocodeine) and benzodiazepines (Diazepam, nordiazepam, oxazepam, bromazepam, flunitrazepam, 7-aminoflunitrazepam, lorazepam) as well as Z-substances (Zolpidem, zopiclone, zaleplon). This way you will receive knowledge about your patient’s drug consumption and concomitant consumption within the shortest amount of time and with only minimal analytical expenditure.
Drug- plus medication screening (abbreviation: DRU3): As per DRU2 with additional testing for tricyclic antidepressants and medication (approximately 4000 substances).
Opioid screening (abbreviation: OPIOIU):
Alcohol markers:
Advantages of the screening methods (DRU1, DRU2, DRU3):
Confirmation analysis for quick screening test: If desired, positive results from an immunochemical quick screening in the urine, obtained in your practice, can be confirmed from the leftover material with a chromatographic method.
Test for new psychoactive substances (NPS): It is possible to demonstrate a large number of modern designer drugs such as synthetic cannabinoids and cathinones as well as tryptamine- and piperazine derivates in the urine with classical methods such as GC-MS as well as with new analytical methods, especially LC-MS/MS and Q-TOF. The spectrum of substances covered is continuously increased. |
More Results for the letter A
- Angina Plaut-Vincenti (APV)
- Treponema vincentii and fusobacterium nucleatum
- ANP (ANP)
- atrial natriuretic peptide
- Anti-actin autoantibodies (ACTIN)
- Anti-alpha fodrin autoantibodies (AFODG)
- Anti-desmoglein 1/3 (DESMO)
- Anti-DNA antibodies (DNADS)
- ds-DNA antibodies (double-stranded)
- Anti-epidermal basal membrane (EPI)
- Anti-goblet cell autoantibodies (BECZE)
- Anti-mitochondrial antibodies (AMA)
- AMA and AMA subtype 2
- Anti-mullarian hormone (AMH)
- Anti-sickle cell desmosomes (STADE)
- Anti-SP100 (SP100)
- multiple nuclear dots
- Antibiogram (ANTIBIO)
- Antibodies against α-amino-3-hydroxy-5-methyl-4-isoxazol-propionic acid receptor (AMPAR)
- Antibodies against adenylate kinase 5 (Ak5)
- Ak5
- Antibodies against contactin-associated protein 2 (CASPR2)
- Antibodies against ganglionic (alpha-3) acetylcholine receptors (gAChR)
- (gAChR)
- Antibodies against glutamate decarboxylase 65 kDa (GAD65)
- Antibodies against leucine-rich glioma inactivated protein 1 (LGI1)
- Antibodies against LRP4
- (low-density lipoprotein receptor-related protein 4)
- Antibodies against myelin oligodendrocyte glycoprotein (MOG)
- Antibodies against N-methyl-D-aspartate receptor receptors (NMDAR)
- Antibodies against oxidized LDL (LDLOX)
- Antibodies against the γ-aminobutyric acid A receptor (GABA-A-R)
- Antibodies against the γ-aminobutyric acid B receptor (GABA-B-R)
- Antibodies against the glial fibrillary acidic protein (GFAP)
- Antibodies against the glycine receptor (GlyR)
- Antibodies against the metabotropic glutamate receptor type 1 (mGluR1 antibodies)
- Antibody screen (ANTI01)
- Antibody screening (AK)
- AKS